PMID- 36973145
OWN - NLM
STAT- MEDLINE
DCOM- 20230612
LR  - 20230612
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 55
IP  - 4
DP  - 2023 May
TI  - Clinical Significance of Plasma Tenascin-C Levels in Recipients With Prolonged 
      Jaundice After Living Donor Liver Transplantation.
PG  - 913-923
LID - S0041-1345(23)00092-1 [pii]
LID - 10.1016/j.transproceed.2023.01.028 [doi]
AB  - BACKGROUND: Focusing on tenascin-C (TNC), whose expression is enhanced during the 
      tissue remodeling process, the present study aimed to clarify whether plasma TNC 
      levels after living donor liver transplantation (LDLT) could be a predictor of 
      irreversible liver damage in the recipients with prolonged jaundice (PJ). 
      METHODS: Among 123 adult recipients who underwent LDLT between March 2002 and 
      December 2016, the subjects were 79 recipients in whom we could measure plasma 
      TNC levels preoperatively (pre-) and on postoperative days 1 to 14 (POD1 to 
      POD14). Prolonged jaundice was defined as serum total bilirubin level >10 mg/dL 
      on POD14, and 79 recipients were divided into 2 groups: 56 in the non-PJ (NJ) 
      group and 23 in the PJ group. RESULTS: The PJ group had significantly increased 
      pre-TNC; smaller grafts; decreased platelet counts POD14; increased TB-POD1, 
      -POD7, and -POD14; increased prothrombin time-international normalized ratio on 
      POD7 and POD14; and higher 90-day mortality than the NJ group. As for the risk 
      factors for 90-day mortality, multivariate analysis identified TNC-POD14 as a 
      single significant independent prognostic factor (P = .015). The best cut-off 
      value of TNC-POD14 for 90-day survival was determined to be 193.7 ng/mL. In the 
      PJ group, the patients with low TNC-POD14 (<193.7 ng/mL) had satisfactory 
      survival, with 100.0 % at 90 days, while the patients with high TNC-POD14 (>/=193.7 
      ng/mL) had significantly poor survival, with 38.5 % at 90 days (P = .004). 
      CONCLUSIONS: In PJ after LDLT, plasma TNC-POD14 is very useful for diagnosing 
      postoperative irreversible liver damage early.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Shinkai, Toru
AU  - Shinkai T
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan; Department of Disaster and 
      Emergency Medicine, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Kuriyama, Naohisa
AU  - Kuriyama N
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan. Electronic address: 
      naokun@med.mie-u.ac.jp.
FAU - Usui, Masanobu
AU  - Usui M
AD  - Department of Palliative Medicine, Fujita Health University Faculty of Medicine, 
      Toyoake, Aichi, Japan.
FAU - Hayasaki, Aoi
AU  - Hayasaki A
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Fujii, Takehiro
AU  - Fujii T
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Iizawa, Yusuke
AU  - Iizawa Y
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Tanemura, Akihiro
AU  - Tanemura A
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Murata, Yasuhiro
AU  - Murata Y
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Kishiwada, Masashi
AU  - Kishiwada M
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Katoh, Daisuke
AU  - Katoh D
AD  - Department of Pathology and Matrix Biology, Mie University Graduate School of 
      Medicine, Tsu, Mie, Japan.
FAU - Matsumoto, Takeshi
AU  - Matsumoto T
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine, Tsu, Mie, Japan.
FAU - Wada, Hideo
AU  - Wada H
AD  - Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Yoshida, Toshimichi
AU  - Yoshida T
AD  - Department of Pathology and Matrix Biology, Mie University Graduate School of 
      Medicine, Tsu, Mie, Japan.
FAU - Isaji, Shuji
AU  - Isaji S
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
FAU - Mizuno, Shugo
AU  - Mizuno S
AD  - Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University 
      Graduate School of Medicine, Tsu, Mie, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230325
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Tenascin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Liver Transplantation/adverse effects
MH  - Tenascin/metabolism
MH  - Living Donors
MH  - Clinical Relevance
MH  - *Jaundice/etiology
COIS- DISCLOSURES All the authors declare no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/03/28 06:00
MHDA- 2023/06/12 06:42
CRDT- 2023/03/27 22:01
PHST- 2022/12/22 00:00 [received]
PHST- 2023/01/26 00:00 [accepted]
PHST- 2023/06/12 06:42 [medline]
PHST- 2023/03/28 06:00 [pubmed]
PHST- 2023/03/27 22:01 [entrez]
AID - S0041-1345(23)00092-1 [pii]
AID - 10.1016/j.transproceed.2023.01.028 [doi]
PST - ppublish
SO  - Transplant Proc. 2023 May;55(4):913-923. doi: 10.1016/j.transproceed.2023.01.028. 
      Epub 2023 Mar 25.